Chemocentryx reported $-31574000 in EBIT for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebit Change
Alnylam Pharmaceuticals ALNY:US $ -191686000 44.95M
Amgen AMGN:US $ 2176M 324M
AstraZeneca AZN:LN 181.11B 36.36B
Bayer BAYN:GR 2.28B 1.89B
Biogen BIIB:US $ 940.9M 409.4M
Biomarin Pharmaceutical BMRN:US $ 39.15M 9.82M
Bristol Myers Squibb BMY:US $ 3197M 9M
Chemocentryx CCXI:US $ -31574000 6.66M
Glaxosmithkline GSK:US 1.82B 600M
GlaxoSmithKline GSK:LN 181.6B 5.9B
Johnson & Johnson JNJ:US $ 6941M 599M
Macrogenics MGNX:US $ -41808000 24.83M
Merk MRK:US $ 5711M 652M
Mirati Therapeutics MRTX:US $ -177205000 7.01M
Novartis NOVN:VX 3.32B 176M
Omeros OMER:US $ -37438000 2.39M
Pfizer PFE:US $ 12099M 2104M
Sarepta Therapeutics SRPT:US $ -211132000 124.25M
Takeda 4502:JP 150.52B 152.13B
Teva Pharmaceutical TEVA:IT 734M 55M
YTE INCY:US $ 260.29M 132.62M